

DAFTAR PUSTAKA

- Alamer, E., Alhazmi, A., Qasir, N. A., Alamer, R., Areeshi, H., Gohal, G., Qadri, M., Hashem, A. M., & Algaissi, A. (2021). *Side Effects of COVID-19 Pfizer-BioNTech mRNA Vaccine in Children Aged 12 – 18 Years in Saudi Arabia. Vaccines*, 2019, 1–11. <https://doi.org/https://doi.org/10.3390/vaccines9111297>
- Ali, K., Berman, G., Zhou, H., Deng, W., Faughnan, V., Coronado-Voges, M., Ding, B., Dooley, J., Girard, B., Hillebrand, W., Pajon, R., Miller, J. M., Leav, B., & McPhee, R. (2021). *Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. New England Journal of Medicine*, 385(24), 2241–2251. <https://doi.org/10.1056/nejmoa2109522>
- Ali Sahraian, M., Ghadiri, F., Azimi, A., & Naser Moghadasi, A. (2021). *Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV. Vaccine*, 39(43), 6347–6350. <https://doi.org/10.1016/j.vaccine.2021.09.030>
- Amin, S., Nugraha, A. C., & Maulidya, S. A. I. (2021). *Skrining Virtual Senyawa Alkaloid Sebagai Inhibitor Main Protease Untuk Kandidat ANTI-SARS-COV-2* (Annisa Nur). Grup Penerbitan CV Budi Utama.
- Amin, S., Nurrohman, F., & Maulidya, S. A. I. (2021). *Skrining Virtual Senyawa Terpenoid Sebagai Inhibitor Main Protease Untuk Kandidat ANTI-SARS-COV-2* (Paramitha). Grup Penerbitan CV Budi Utama.
- Anies. (2020). *Covid-19 seluk beluk corona virus* (Mikah (ed.); Nur Hidayah). ARRUIZ MEDIA.
- Anies, Setyowati, R., Fadhila, N., & Arif, K. (2021). *COVID-19: Tinjauan Covid-19 dari Aspek Kesehatan, Ekonomi dan Hukum* (T. Gosyen (ed.)). Gosyen Publishing.
- Ariamanesh, M., Porouhan, P., PeyroShabany, B., Fazilat-Panah, D., Dehghani, M., Nabavifard, M., Hatami, F., Fereidouni, M., Welsh, J. S., & Javadinia, S. A. (2022). *Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy. Cancer Investigation*, 40(1), 26–34. <https://doi.org/10.1080/07357907.2021.1992420>
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., ... Zaks, T. (2021). *Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine*, 384(5), 403–416. <https://doi.org/10.1056/nejmoa2035389>
- Bar-On, Y. M., Goldberg, Y., Mandel, M., Bodenheimer, O., Freedman, L., Kalkstein, N., Mizrahi, B., Alroy-Preis, S., Ash, N., Milo, R., & Huppert, A. (2021). *Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. New England Journal of Medicine*, 385(15), 1393–1400. <https://doi.org/10.1056/nejmoa2114255>

- Baraniuk, C. (2021). *What do we know about China's covid-19 vaccines? The BMJ*, 373, 59–60. <https://doi.org/10.1136/bmj.n912>
- Bhatt, T., Kumar, V., Pande, S., Malik, R., Khamparia, A., & Gupta, D. (2021). A Review on COVID-19. *Studies in Computational Intelligence*, 924(April), 25–42. https://doi.org/10.1007/978-3-030-60188-1_2
- Bravo, L., Smolenov, I., Han, H. H., Li, P., Hosain, R., Rockhold, F., Clemens, S. A. C., Roa, C., Borja-Tabora, C., Quinsa, A., Lopez, P., López-Medina, E., Brochado, L., Hernández, E. A., Reynales, H., Medina, T., Velasquez, H., Toloza, L. B., Rodriguez, E. J., ... Clemens, R. (2022). *Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. The Lancet*, 399(10323), 461–472. [https://doi.org/10.1016/s0140-6736\(22\)00055-1](https://doi.org/10.1016/s0140-6736(22)00055-1)
- Bruusgaard-Mouritsen, M. A., Koo, G., Heinrichsen, A. S., Melchior, B. B., Krantz, M. S., Plager, J. H., Boxer, M., Phillips, E. J., Stone, C. A., & Garvey, L. H. (2022). *Janssen COVID-19 vaccine tolerated in 10 patients with confirmed polyethylene glycol allergy. Journal of Allergy and Clinical Immunology: In Practice*, 1(patient 7), 1–4. <https://doi.org/10.1016/j.jaip.2021.12.025>
- Burns, K. E. A., Laird, M., Stevenson, J., Honarmand, K., & Granton, D. (2021). *Adherence of Clinical Practice Guidelines for Pharmacologic Treatments of Hospitalized Patients With COVID-19 to Trustworthy Standards A Systematic Review*. 4(12), 1–15. <https://doi.org/10.1001/jamanetworkopen.2021.36263>
- Carl, Zimmer, Corum, J., Wee, S.-L., & Kristoffersen, and M. (2022). *Coronavirus Vaccine Tracker. The New York Times*. <https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html>
- CDC. (2021a). *Safety of COVID-19 Vaccines*. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/safety-of-vaccines.html>
- CDC. (2021b). *Symptoms of COVID-19*. <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>
- Chumaida, Z. V., Ariadi, B. S., & Roro, F. S. R. (2021). *Penanganan Pelayanan Kesehatan di Masa Pandemi COVID-19* (T. Lestari & D. Wandana (eds.)). CV. Jakad Media Publishing. https://www.google.co.id/books/edition/Penanganan_Pelayanan_Kesehatan_di_Masa_P/PyBAEAAAQBAJ?hl=id&gbpv=1
- CNBC. (2021a). *Kabar Baik! Vaksin Sinopharm & CanSino Tiba Minggu ke-4 April*. Consumer News and Business Channel. <https://www.cnbcindonesia.com/news/20210408160732-4-236310/kabar-baik-vaksin-sinopharm-cansino-tiba-minggu-ke-4-april>
- CNBC. (2021b). *Peneliti Ungkap Vaksin J&J Ampuh Lawan Covid-19*. Consumer News and Business Channel. <https://www.cnbcindonesia.com/news/20210806190251-4-266809/peneliti-ungkap-vaksin-jj-ampuh-lawan-covid-19>

- CNBC. (2021c). *Studi: Vaksin Pfizer Ampuh Lawan Covid Delta di Usia Remaja*. Consumer News and Business Channel. <https://www.cnbcindonesia.com/news/20211021183303-4-285619/studi-vaksin-pfizer-ampuh-lawan-covid-delta-di-usia-remaja>
- CNN. (2021). *Kenali Efek Samping Vaksin Covid-19 Moderna*. Cable News Network Indonesia. <https://www.cnnindonesia.com/gaya-hidup/20210825154910-255-685272/kenali-efek-samping-vaksin-covid-19-moderna>
- Costa Clemens, S. A., Weckx, L., Clemens, R., Almeida Mendes, A. V., Ramos Souza, A., Silveira, M. B. V., da Guarda, S. N. F., de Nobrega, M. M., de Moraes Pinto, M. I., Gonzalez, I. G. S., Salvador, N., Franco, M. M., de Avila Mendonça, R. N., Queiroz Oliveira, I. S., de Freitas Souza, B. S., Fraga, M., Aley, P., Bibi, S., Cantrell, L., ... de Arruda Cordeiro Matos, L. J. (2022). *Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study*. *The Lancet*, 399(10324), 521–529. [https://doi.org/10.1016/s0140-6736\(22\)00094-0](https://doi.org/10.1016/s0140-6736(22)00094-0)
- Dafiyanti, M., Fikri, M., Shodiq, M. J., Pangestu, A., Sofian, A., Aulady, A. A., Desi, A. F., Sodikin, T. R., Al-Ayyubi, T. M. Z. A., Aiman, U., Kurnia, V., Febrianti, W., Fahrani, D., Permana, D., Sartika, D., Yopitasari, D., Suwandini, C. P., Carolina, C. E., Hayyah, D. A. A., & Ariska, D. (2021). *Vaksinasi dan Stigma Masyarakat di Masa Pandemi* (A. Ansori (ed.)). Farha Pustaka. https://www.google.co.id/books/edition/Vaksinasi_Dan_Setigma_Masyarakat_Dimasa/9sjmeaaaqbaJ?hl=id&gbpv=1&dq=vaksin+covid-19&pg=PT55&printsec=frontcover
- Daud, A., Syam, A., Arsin, A. A., & Hanafiah, S. S. (2020). *Penanganan Coronavirus (Covid-19) Ditinjau Dari Perspektif Kesehatan Masyarakat* (Gosyen Tim (ed.); Andy Gp). Gasyen Publising.
- Dickerman, B. A., Gerlovin, H., Madenci, A. L., Kurgansky, K. E., Ferolito, B. R., Figueroa Muñiz, M. J., Gagnon, D. R., Gaziano, J. M., Cho, K., Casas, J. P., & Hernán, M. A. (2022). *Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans*. *New England Journal of Medicine*, 386(2), 105–115. <https://doi.org/10.1056/nejmoa2115463>
- Edara, V. V., Manning, K. E., Ellis, M., Lai, L., Moore, K. M., Foster, S. L., Floyd, K., Davis-Gardner, M. E., Mantus, G., Nyhoff, L. E., Bechnak, S., Alaaeddine, G., Naji, A., Samaha, H., Lee, M., Bristow, L., Gagne, M., Roberts-Torres, J., Henry, A. R., ... Suthar, M. S. (2022). *mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant*. *Cell Reports Medicine*, 3(2), 100529. <https://doi.org/10.1016/j.xcrm.2022.100529>
- ElBagoury, M., Tolba, M. M., Nasser, H. A., Jabbar, A., Elagouz, A. M., Aktham, Y., & Hutchinson, A. (2021). *The find of COVID-19 vaccine: Challenges and opportunities*. *Journal of Infection and Public Health*, 14(3), 389–416. <https://doi.org/10.1016/j.jiph.2020.12.025>

- FDA. (2020). *FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine*. FDA NEWS RELEASE.
- FDA. (2022). *Moderna COVID-19 Vaccine (updated 31 January 2022)*. Food and Drug Administration. <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/spikevax-and-moderna-covid-19-vaccine>
- Ferenci, T., & Sarkadi, B. (2021). *Virus neutralizing antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine*. *MedRxiv The Preprint Server For Health Sciences*. <https://www.medrxiv.org/content/10.1101/2021.07.15.21260362v2.full-text>
- Food and Drug Administration. (2020). *Development and Licensure of Vaccines to Prevent COVID-19 Guidance for Industry*. June, 1–24. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19>
- Garrison, C. (2020). *How the 'Oxford' Covid-19 vaccine became the 'AstraZeneca' Covid-19 vaccine* | Medicines Law & Policy. *Medicines Law & Policy*. <https://medicineslawandpolicy.org/2020/10/how-the-oxford-covid-19-vaccine-became-the-astrazeneca-covid-19-vaccine/>
- Gee, J., Shimabukuro, P. M., Su, J., Tom, G. M. C., Sotir, R., Mark, g L., Jazwa, T. M., Amelia, N. N., Licata, S. M., Clark, T., Markowitz, L., Lindsey, N., & Zhang, B. C. (2021). *First Month of COVID-19 Vaccine Safety Monitoring — United States*. *MMWR. Morbidity and Mortality Weekly Report*, 70(8), 283–288.
- Gupta, R. K., & Topol, E. J. (2021). *COVID-19 vaccine breakthrough infections*. *Science*, 374(6575), 1561–1562. <https://doi.org/10.1126/science.abl8487>
- Hakiki, M., Widiyastuti, N. E., & Danti, R. R. (2022). *Asuhan Kehamilan Sehat Selama Pandemi COVID-19* (M. Hakiki, N. E. Widiyastuti, & R. R. Danti (eds.)). Guepedia The First On-Publisher in Indonesia. https://www.google.co.id/books/edition/Buku_Ajar_Asuhan_Kehamilan_Sehat_Selama/dejyeeaaqbaj?hl=id&gbpv=1&dq=vaksin+covid-19&pg=PA342&printsec=frontcover
- Haque, A., & Pant, A. B. (2020). *Efforts at COVID-19 vaccine development: Challenges and successes*. *Vaccines*, 8(4), 1–16. <https://doi.org/10.3390/vaccines8040739>
- Haurora, M. (2021). *About COVID-19*. Ministry Of Health Manatu Hauora. <https://www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-health-advice-public/about-covid-19>
- He, Q., Mao, Q., An, C., Zhang, J., Gao, F., Bian, L., Li, C., Liang, Z., Xu, M., & Wang, J. (2021). *Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates*. *Emerging Microbes and Infections*, 10(1), 629–637. <https://doi.org/10.1080/22221751.2021.1902245>

- Heriyanto, R. S., Kurniawan, A., Wijovi, F., Halim, D. A., Jodhinata, C., Marcella, E., Susanto, B., Wibowo, J., Indrawan, M., Heryadi, N. K., Imanuelly, M., Anurantha, J. J., Hariyanto, T. I., Marcellin, C., Sinaga, T. D., Rizki, S. A., Sieto, N., Siregar, J. I., & Lugito, N. P. H. (2021). *The role of COVID-19 survivor status and gender towards neutralizing antibody titers 1, 2, 3 months after Sinovac vaccine administration on clinical-year medical students in Indonesia: Role of COVID-19 survivor status and gender towards neutralizing antib. International Journal of Infectious Diseases, 113*, 336–338. <https://doi.org/10.1016/j.ijid.2021.10.009>
- Herzog Tzarfati, K., Gutwein, O., Apel, A., Rahimi-Levene, N., Sadovnik, M., Harel, L., Benveniste-Levkovitz, P., Bar Chaim, A., & Koren-Michowitz, M. (2021). *BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies. American Journal of Hematology, 96*(10), 1195–1203. <https://doi.org/10.1002/ajh.26284>
- Hill, E. M., & Keeling, M. J. (2021). *Comparison between one and two dose SARS-CoV-2 vaccine prioritization for a fixed number of vaccine doses. Journal of the Royal Society Interface, 18*(182). <https://doi.org/10.1098/rsif.2021.0214>
- Hossian, M., Khan, M. A. S., Nazir, A., Nabi, M. H., Hasan, M., Maliha, R., Hossain, M. A., Rashid, M. U., Itrat, N., & Hawlader, M. D. H. (2022). *Factors affecting intention to take COVID-19 vaccine among Pakistani University Students. PLoS ONE, 17*(2 February), 1–17. <https://doi.org/10.1371/journal.pone.0262305>
- Hotez, P. J., Nuzhath, T., Callaghan, T., & Colwell, B. (2021). *COVID-19 vaccine decisions: considering the choices and opportunities. Microbes and Infection, 23*(4–5). <https://doi.org/10.1016/j.micinf.2021.104811>
- Hwang, J. K., Zhang, T., Wang, A. Z., & Li, Z. (2021). *COVID-19 vaccines for patients with cancer: benefits likely outweigh risks. Journal of Hematology and Oncology, 14*(1), 1–11. <https://doi.org/10.1186/s13045-021-01046-w>
- Ioannidis, J. P. A. (2022). *Factors influencing estimated effectiveness of COVID-19 vaccines in non-randomised studies. BMJ Evidence-Based Medicine, 0*(0), bmjebm-2021-111901. <https://doi.org/10.1136/bmjebm-2021-111901>
- Irwan. (2020). *Guratan Pandemi* (Sukarjo & B. Soepriyadi (eds.)). PT Pustaka Alvabet Anggota IKAPI.
- Jackson, L. A., Anderson, E. J., Roupshael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., McDermott, A., Flach, B., Doria-Rose, N. A., Corbett, K. S., Morabito, K. M., O'Dell, S., Schmidt, S. D., Swanson, P. A., ... Beigel, J. H. (2020). *An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. New England Journal of Medicine, 383*(20), 1920–1931. <https://doi.org/10.1056/nejmoa2022483>
- Jara, A., Undurraga, E. A., González, C., Paredes, F., Fontecilla, T., Jara, G., Pizarro, A., Acevedo, J., Leo, K., Leon, F., Sans, C., Leighton, P., Suárez, P., García-Escorza, H., & Araos, R. (2021). *Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. New England Journal of Medicine, 385*(10), 875–

884. <https://doi.org/10.1056/nejmoa2107715>

- Jochum, S., Kirste, I., Hortsch, S., Grunert, V. P., Legault, H., Kashlan, B., Pajon, R., Jochum, S., & Gmbh, R. D. (2021). *Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19 vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial Roche Diagnostics GmbH, Penzberg, Germany; 2 Roche Diagnostics Operations, Correspondence: Rolando Pajon Email: rola.*
- Kadali, R. A. K., Janagama, R., Peruru, S., Gajula, V., Madathala, R. R., Chennaiahgari, N., & Malayala, S. V. (2021). *Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms. Journal of Medical Virology, 93(7), 4420–4429.* <https://doi.org/10.1002/jmv.26996>
- Karami, A. F., & Efendi, D. (2020). *Membaca Corona: Esai-Esai tentang Manusia, Wabah, dan Dunia* (Caremedia). Caremedia Communication. https://www.google.co.id/books/edition/Membaca_Korona_Esai_Esai_tentan_g_Manusia/W8TgDwAAQBAJ?hl=id&gbpv=1&dq=vaksin+covid-19&printsec=frontcover
- Kemkes (Kementerian Kesehatan) RI. (2021). *Apa Yang Harus Dilakukan Bila Terjadi Reaksi KIPI Setelah Vaksinasi?* Pusat Analisis Determinan Kesehatan Kementerian Kesehatan Republik Indonesia. <http://www.padk.kemkes.go.id/news/read/2021/06/02/633/apa-yang-harus-dilakukan-bila-terjadi-reaksi-kipi-setelah-vaksinasi.html#:~:text=KIPI atau Kejadian Ikutan Pasca,terkait dengan imunisasi atau vaksinasi>
- Kemkes (Kementrian Kesehatan) RI. (2021). *Buku Saku Tanya Jawab Seputar Vaksinasi Covid-19 Edisi Pertama (2021).* In *Direktorat Jenderal Pencegahan dan Pengendalian Penyakit.*
- Khan, M., Adil, S. F., Alkathlan, H. Z., Tahir, M. N., Saif, S., Khan, M., & Khan, S. T. (2020). *COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far. Molecules (Basel, Switzerland), 26(1), 1–25.* <https://doi.org/10.3390/molecules26010039>
- Kim, J. H., Marks, F., & Clemens, J. D. (2021). *Looking beyond COVID-19 vaccine phase 3 trials. Nature Medicine, 27(2), 205–211.* <https://doi.org/10.1038/s41591-021-01230-y>
- Koirala, A., Jin, Y., Khatami, A., Chiu, C., & Britton, P. N. (2020). *Vaccines for COVID-19: The current state of play. Paediatric Respiratory Reviews, 35, 43–49.* <https://doi.org/10.1016/j.prrv.2020.06.010>
- Kostoff, R. N., Briggs, M. B., Porter, A. L., Spandidos, D. A., & Tsatsakis, A. (2020). *Comment: COVID-19 vaccine safety. International Journal of Molecular Medicine, 46(5), 1599–1602.* <https://doi.org/10.3892/ijmm.2020.4733>
- Krause, P., Fleming, T. R., Longini, I., Henao-Restrepo, A. M., Peto, R., Dean, N. E., Halloran, M. E., Huang, Y., Fleming, T. R., Gilbert, P. B., DeGruttola, V., Janes, H. E., Krause, P. R., Longini, I. M., Nason, M. C., Peto, R., Smith, P. G., Riveros, A. X., Gsell, P. S., & Henao-Restrepo, A. M. (2020). *COVID-19*

- vaccine trials should seek worthwhile efficacy. *The Lancet*, 396(10253), 741–743. [https://doi.org/10.1016/S0140-6736\(20\)31821-3](https://doi.org/10.1016/S0140-6736(20)31821-3)
- Lau, C. L., Mayfield, H. J., Sinclair, J. E., Brown, S. J., Waller, M., Enjeti, A. K., Baird, A., Short, K. R., Mengersen, K., & Litt, J. (2021). *Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework*. *Vaccine*, 39(51), 7429–7440. <https://doi.org/10.1016/j.vaccine.2021.10.079>
- Liu, C., Zhou, Q., Li, Y., Garner, L. V., Watkins, S. P., Carter, L. J., Smoot, J., Gregg, A. C., Daniels, A. D., Jervey, S., & Albaiu, D. (2020). *Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases*. *ACS Central Science*, 6(3), 315–331. <https://doi.org/10.1021/acscentsci.0c00272>
- Liu, Y., Liu, J., Xia, H., Zhang, X., Fontes-Garfias, C. R., Swanson, K. A., Cai, H., Sarkar, R., Chen, W., Cutler, M., Cooper, D., Weaver, S. C., Muik, A., Sahin, U., Jansen, K. U., Xie, X., Dormitzer, P. R., & Shi, P.-Y. (2021). *Neutralizing Activity of BNT162b2-Elicited Serum*. *New England Journal of Medicine*, 384(15), 1466–1468. <https://doi.org/10.1056/nejmc2102017>
- Livingston, E. H., Malani, M. P. N., MD, M. C. B. C., & MD, M. (2021). *The Johnson & Johnson Vaccine for COVID-19*. *JAMA Network*. <https://jamanetwork.com/journals/jama/fullarticle/2777172/>
- Lospinoso, K., Nichols, C. S., Malachowski, S. J., Mochel, M. C., & Nutan, F. (2021). *A case of severe cutaneous adverse reaction following administration of the Janssen Ad26.COV2.S COVID-19 vaccine*. *JAAD Case Reports*, 13, 134–137. <https://doi.org/10.1016/j.jdc.2021.05.010>
- MacNeil, J. R., MPH1; John R. Su, MD, PhD1; Karen R. Broder, MD1; Alice Y. Guh, MD1; Julia W. Gargano, PhD1; Megan Wallace, D., Stephen C. Hadler, MD1; Heather M. Scobie, PhD1; Amy E. Blain, MPH1; Danielle Moulia, MPH1; Matthew F. Daley, MD2; Veronica V. McNally, J., & José R. Romero, MD4; H. Keipp Talbot, MD5; Grace M. Lee, MD6; Beth P. Bell, MD7; Sara E. Oliver, M. (2021). *Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021*. *Center for Disease Control and Prevention MMWR*, 70. https://www.cdc.gov/mmwr/volumes/70/wr/mm7017e4.htm?s_cid=mm7017e4_w
- Marzo, R. R., Ahmadnd, A., Islam, M. S., Essar, M. Y., Heidler, P., King, I., Thiagarajan, A., Jermittiparsert, K., Songwathana, K., Younusnd, D. A., El-Abasirib, R. A., Kucukbicer, B., Phamb, N., Respatib, T., Fitriyana, S., Martinez Faller, E., Baldonado, A. M., Billah, M. A., Aung, Y., ... Yi, S. (2022). *Perceived COVID-19 vaccine effectiveness, acceptance, and drivers of vaccination decision-making among the general adult population: A global survey of 20 countries*. *PLoS Neglected Tropical Diseases*, 16(1), 1–16. <https://doi.org/10.1371/journal.pntd.0010103>
- Marzuki, I., Bachtiar, E., Zuhriyatun, F., Purba, A. M. V., Kurniasih, H., Purba, D.

- H., Chamidah, D., Jamaludin, Purba, B., Puspita, R., Chaerul, M., Basmar, E., Sianturi, E., Sulaeman, A. R., Nasrullah, Hastuti, P., Mastutie, F., Purba, S., Rahmadani, M. F., & Airlangga, E. (2021). *COVID-19: Seribu Satu Wajah* (A. Karim & J. Simarmata (eds.); Tim Kreati). Yayasan Kita Menulis.
- Mascellino, M. T., Di Timoteo, F., De Angelis, M., & Oliva, A. (2021). Overview of the main anti-sars-cov-2 vaccines: Mechanism of action, efficacy and safety. *Infection and Drug Resistance*, *14*, 3459–3476. <https://doi.org/10.2147/IDR.S315727>
- Mathieu, E., Ritchie, H., Ortiz-Ospina, E., Roser, M., Hasell, J., Appel, C., Giattino, C., & Rodés-Guirao, L. (2021). A global database of COVID-19 vaccinations. *Nature Human Behaviour*, *5*(7), 947–953. <https://doi.org/10.1038/s41562-021-01122-8>
- Meo, S. A., Bukhari, I. A., Akram, J., Meo, A. S., & Klonoff, D. C. (2021). COVID-19 vaccines: Comparison of biological, pharmacological characteristics and adverse effects of pfizer/BioNTech and moderna vaccines. *European Review for Medical and Pharmacological Sciences*, *25*(3), 1663–1679. https://doi.org/10.26355/eurrev_202102_24877
- Moghnieh, R., Mekdashi, R., El-Hassan, S., Abdallah, D., Jisr, T., Bader, M., Jizi, I., H.Sayegh, M., & Bizri, A. R. (2021). Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon. *Vaccine*.
- Muik, A., Ph.D., Ugur Sahin, M. D., Yang Liu, P. D., Jianying Liu, P. D., Hongjie Xia, P. D., Xianwen Zhang, B. S., Camila R. Fontes-Garfias, P. D., Kena A. Swanson, P. D., Hui Cai, P. D., Ritu Sarkar, M. A., Wei Chen, M. S., Mark Cutler, P. D., & David Cooper, P. D. (2021). Neutralizing Activity of BNT162b2-Elicited Seru. *The New England Journal of Medicine*.
- Mullard, A. (2020). COVID-19 vaccine development pipeline gears up. *Lancet (London, England)*, *395*(10239), 1751–1752. [https://doi.org/10.1016/S0140-6736\(20\)31252-6](https://doi.org/10.1016/S0140-6736(20)31252-6)
- Ndwandwe, D., & Wiysonge, C. S. (2021). COVID-19 vaccines. *Current Opinion in Immunology*, *71*(Figure 1), 111–116. <https://doi.org/10.1016/j.coi.2021.07.003>
- Nidom, R. V., Ansori, A. N. M., Indrasari, S., Normalina, I., Kusala, M. K. J., Saefuddin, A., & Nidom, C. A. (2020). Recent Updates on COVID-19 Vaccine Platforms and Its Immunological Aspects: A Review. *Systematic Reviews in Pharmacy*, *11*(10), 807–818. <https://doi.org/10.31838/srp.2020.10.121>
- Nuryati. (2017). Bahan Ajar Rekam Medis Dan Informasi Kesehatan (Rmik) Farmakologi. In *Kementrian Kesehatan Republik Indonesia*.
- Oliver, S. E., Gargano, J. W., Scobie, H., Wallace, M., Hadler, S. C., Leung, J., Blain, A. E., McClung, N., Campos-Outcalt, D., Morgan, R. L., Mbaeyi, S., MacNeil, J., Romero, J. R., Keipp Talbot, H., Lee, G. M., Bell, B. P., & Dooling, K. (2021). Morbidity and Mortality Weekly Report The Advisory Committee on Immunization Practices' Interim Recommendation for Use of

- Janssen COVID-19 Vaccine. Morbidity and Mortality Weekly Report*, 70(9), 329–332.
- Pan, H., Wu, Q., Zeng, G., Yang, J., Jiang, D., Deng, X., Chu, K., Zheng, W., Zhu, F., Yu, H., & Yin, W. (2021). *Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial. MedRxiv.*
- Pandey, V., Singh, A., Siddiqui, S., Raikwar, A., Gond, A. K., Ali, S., Yadav, M., Datta, A., & Singh, A. (2021). COVID-19: An update of current knowledge (Review). *World Academy of Sciences Journal*, 3(2), 1–8. <https://doi.org/10.3892/wasj.2021.86>
- Peeples, L. (2020). *Avoiding pitfalls in the pursuit of a COVID-19 vaccine. Proceedings of the National Academy of Sciences of the United States of America*, 117(15), 8218–8221. <https://doi.org/10.1073/pnas.2005456117>
- Persad, G., & Emanuel, E. J. (2021). *Ethical Considerations of Offering Benefits to COVID-19 Vaccine Recipients. JAMA - Journal of the American Medical Association*, 326(3), 221–222. <https://doi.org/10.1001/jama.2021.11045>
- Platto, S., Wang, Y., Zhou, J., & Carafoli, E. (2021). *History of the COVID-19 pandemic: Origin, explosion, worldwide spreading. Biochemical and Biophysical Research Communications*, 538, 14–23. <https://doi.org/10.1016/j.bbrc.2020.10.087>
- Rahman, M. M., Masum, M. H. U., Wajed, S., & Talukder, A. (2022). *A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges. VirusDisease*, 33(1), 1–22. <https://doi.org/10.1007/s13337-022-00755-1>
- Rapaka, R. R., Hammershaimb, E. A., & Neuzil, K. M. (2022). *Are Some COVID-19 Vaccines Better Than Others? Interpreting and Comparing Estimates of Efficacy in Vaccine Trials. Clinical Infectious Diseases*, 74(2), 352–358. <https://doi.org/10.1093/cid/ciab213>
- Rashedi, R., Samieefar, N., Masoumi, N., Mohseni, S., & Rezaei, N. (2021). *COVID-19 vaccines mix-and-match: The concept, the efficacy and the doubts. Journal of Medical Virology*, September, 1–6. <https://doi.org/10.1002/jmv.27463>
- Rawat, K., Kumari, P., & Saha, L. (2021). *COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. European Journal of Pharmacology*, 892(November 2020), 173751. <https://doi.org/10.1016/j.ejphar.2020.173751>
- Riad, A., Pokorná, A., Attia, S., Klugarová, J., Koščík, M., & Klugar, M. (2021). *Prevalence of covid-19 vaccine side effects among healthcare workers in the Czech Republic. Journal of Clinical Medicine*, 10(7), 1–18. <https://doi.org/10.3390/jcm10071428>
- Riad, Abanoub, Sağiroğlu, D., Üstün, B., Pokorná, A., Klugarová, J., Attia, S., & Klugar, M. (2021). *Article prevalence and risk factors of coronavac side*

- effects: An independent cross-sectional study among healthcare workers in turkey. Journal of Clinical Medicine, 10(12), 1–13.*
<https://doi.org/10.3390/jcm10122629>
- Romero-Brufau, S., Chopra, A., Ryu, A. J., Gel, E., Raskar, R., Kremers, W., Anderson, K. S., Subramanian, J., Krishnamurthy, B., Singh, A., Pasupathy, K., Dong, Y., O'Horo, J. C., Wilson, W. R., Mitchell, O., & Kingsley, T. C. (2021). *Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: Simulation agent based modeling study. The BMJ, 373.* <https://doi.org/10.1136/bmj.n1087>
- Sabrina, D. S. dkk. (2020). Buku Praktis Penyakit Virus Corona 19 (COVID-19). In *Journal of Chemical Information and Modeling* (Vol. 53, Issue 9).
- Saeed, B. Q., Al-Shahrabi, R., Alhaj, S. S., Alkokhardi, Z. M., & Adrees, A. O. (2021). *Side effects and perceptions following Sinopharm COVID-19 vaccination. International Journal of Infectious Diseases, 111, 219–226.* <https://doi.org/10.1016/j.ijid.2021.08.013>
- Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., Pascal, K. E., Maurus, D., Brachtendorf, S., Lörks, V., Sikorski, J., Koch, P., Hilker, R., Becker, D., Eller, A. K., ... Türeci, Ö. (2021). *BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature, 595(7868), 572–577.* <https://doi.org/10.1038/s41586-021-03653-6>
- Saletti-cuesta, L., Abraham, C., Sheeran, P., Adiyoso, W., Wilopo, W., Brossard, D., Wood, W., Cialdini, R., Groves, R. M., Chan, D. K. C., Zhang, C. Q., Josefsson, K. W., Cori, L., Bianchi, F., Cadum, E., Anthonj, C., Sciences, N. O. of B. and S., Deci, E. L., Ryan, R. M., ... IOTC. (2020). *Subject: Press Conference of WHO-China Joint Mission on COVID-19. Sustainability (Switzerland), 4(1), 1–9.*
- Satgas Covid-19. (2021). Pengendalian Covid-19. In *Satuan Tugas Penanganan Covid-19* (Vol. 53, Issue 9).
- Satgas COVID-19. (2021). *Apa Yang Harus Dilakukan Bila Terjadi Reaksi KIPi Setelah Vaksinasi? COVID-19 Hotline.* <https://covid19.go.id/edukasi/kipi/apa-yang-harus-dilakukan-bila-terjadi-reaksi-kipi-setelah-vaksinasi>
- Setiawan, D. E. (2021). *Gereja di Tempat Pandemi COVID-19* (P. Kreatif (ed.)). KBM Indonesia Anggota IKAPI. https://www.google.co.id/books/edition/Gereja_di_Tengah_Pandemi_Covid_19/E88qEAAAQBAJ?hl=id&gbpv=1&dq=vaksin+covid-19&pg=PA23&printsec=frontcover
- Shakoor, M. T., Birkenbach, M. P., & Lynch, M. (2021). ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine. *American Journal of Kidney Diseases, 78(4), 611–613.* <https://doi.org/10.1053/j.ajkd.2021.06.016>
- Smith, A. W., Ph, D., & Mulholland, K. (2021). *Edi t o r i a l s Effectiveness of an Inactivated SARS-CoV-2 Vaccine. 946–948.*

- Strizova, Z., Smetanova, J., Bartunkova, J., & Milota, T. (2021). *Principles and Challenges in anti-COVID-19 Vaccine Development*. *International Archives of Allergy and Immunology*, 182(4), 339–349. <https://doi.org/10.1159/000514225>
- Tanriover, M. D., Doğanay, H. L., Akova, M., Güner, H. R., Azap, A., Akhan, S., Köse, Ş., Erdiñç, F. Ş., Akalın, E. H., Tabak, Ö. F., Pullukçu, H., Batum, Ö., Şimşek Yavuz, S., Turhan, Ö., Yıldırım, M. T., Köksal, İ., Taşova, Y., Korten, V., Yılmaz, G., ... Aksu, K. (2021). *Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey*. *The Lancet*, 398(10296), 213–222. [https://doi.org/10.1016/S0140-6736\(21\)01429-X](https://doi.org/10.1016/S0140-6736(21)01429-X)
- Thames, A. H., Wolniak, K. L., Stupp, S. I., & Jewett, M. C. (2020). *Principles learned from the international race to develop a safe and effective covid-19 vaccine*. *ACS Central Science*, 6(8), 1341–1347. <https://doi.org/10.1021/acscentsci.0c00644>
- Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., Kuntz, J. L., Dunnigan, K., Odean, M. J., Hegmann, K. T., Stefanski, E., Edwards, L. J., Schaefer-Solle, N., Grant, L., Ellingson, K., ... Gaglani, M. (2021). *Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March*. *MMWR Surveillance Summaries*, 70(13), 495–500. <https://doi.org/10.15585/mmwr.mm7013e3>
- Torjesen, I. (2021). Covid-19: AstraZeneca vaccine is approved in EU with no upper age limit. *BMJ (Clinical Research Ed.)*, 372(February), n295. <https://doi.org/10.1136/bmj.n295>
- Trimpert, J., Adler, J. M., Eschke, K., Abdelgawad, A., Firsching, T. C., Ebert, N., Thao, T. T. N., Gruber, A. D., Thiel, V., Osterrieder, N., & Kunec, D. (2021). *Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta)*. *Science Advances*, 7(49), 1–10. <https://doi.org/10.1126/sciadv.abk0172>
- Vallée, A., Chan-Hew-Wai, A., Bonan, B., Lesprit, P., Parquin, F., Catherinot, Choucair, J., Billard, D., Amiel-Taieb, C., Camps, Cerf, C., Zucman, D., & Fourn, E. (2021). *Oxford–AstraZeneca COVID-19 vaccine: need of a reasoned and effective vaccine campaign*. *Public Health*, 196(February), 135–137. <https://doi.org/10.1016/j.puhe.2021.05.030>
- Vokó, Z., Kiss, Z., Surján, G., Surján, O., Barcza, Z., Pályi, B., Formanek-Balku, E., Molnár, G. A., Herczeg, R., Gyenesei, A., Miseta, A., Kollár, L., Wittmann, I., Müller, C., & Kásler, M. (2021). *Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary—the HUN-VE study*. *Clinical Microbiology and Infection*, xxx. <https://doi.org/10.1016/j.cmi.2021.11.011>
- Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., Bibi, S., Briner,

- C., Cicconi, P., Collins, A. M., Colin-Jones, R., Cutland, C. L., Darton, T. C., Dheda, K., Duncan, C. J. A., ... Zuidewind, P. (2021). *Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet*, 397(10269), 99–111. [https://doi.org/10.1016/S0140-6736\(20\)32661-1](https://doi.org/10.1016/S0140-6736(20)32661-1)
- Wahyuni, T. (2020). *COVID-19 Fakta-Fakta yang Harus Kamu Ketahui tentang Corona Virus* (Z. Ali (ed.)). Pustaka Anak Bangsa.
- Walsh, E. E., Frenck, R. W., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., Swanson, K. A., Li, P., Koury, K., Kalina, W., Cooper, D., Fontes-Garfias, C., Shi, P.-Y., Türeci, Ö., Tompkins, K. R., ... Gruber, W. C. (2020). *Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England Journal of Medicine*, 383(25), 2439–2450. <https://doi.org/10.1056/nejmoa2027906>
- Walter, E. B., Talaat, K. R., Sabharwal, C., Gurtman, A., Lockhart, S., Paulsen, G. C., Barnett, E. D., Muñoz, F. M., Maldonado, Y., Pahud, B. A., Domachowske, J. B., Simões, E. A. F., Sarwar, U. N., Kitchin, N., Cunliffe, L., Rojo, P., Kuchar, E., Rämets, M., Munjal, I., ... Gruber, W. C. (2022). *Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. New England Journal of Medicine*, 386(1), 35–46. <https://doi.org/10.1056/nejmoa2116298>
- Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., & Peng, Z. (2020). *Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - Journal of the American Medical Association*, 323(11), 1061–1069. <https://doi.org/10.1001/jama.2020.1585>
- Wang, J., Jing, R., Lai, X., Zhang, H., Lyu, Y., Knoll, M. D., & Fang, H. (2020). *Acceptance of covid-19 vaccination during the covid-19 pandemic in china. Vaccines*, 8(3), 1–14. <https://doi.org/10.3390/vaccines8030482>
- Wasilyastuti, W., Dhamarjati, A., & Siswanto. (2019). *Imunosenesens dan Kerentanan Populasi Usia Lanjut Terhadap Coronavirus Disease 2019 (Covid-19). Respirologi Indonesia*, 40(3), 182–191.
- Wenhong, Z. (2020). *Panduan Pencegahan Dan Pengawasan Covid-19* (B. Pasaribu & A. Harris (eds.)). Papas Sinar Sinanti.
- WHO. (2020). *How do vaccines work?* <https://www.who.int/news-room/feature-stories/detail/how-do-vaccines-work>
- WHO. (2021a). *COVID-19 advice for the public: Getting vaccinated.* <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice>
- WHO. (2021b). *How do vaccines work?* <https://www.who.int/news-room/feature-stories/detail/how-do-vaccines-work>
- WHO. (2021c). *Interim statement on booster doses for COVID-19 vaccination*

- (Update 22 December 2021). World Health Organization. <https://www.who.int/news/item/22-12-2021-interim-statement-on-booster-doses-for-covid-19-vaccination---update-22-december-2021>
- WHO. (2021d). *Interim statement on COVID-19 vaccination for children and adolescents*. <https://www.who.int/news/item/24-11-2021-interim-statement-on-covid-19-vaccination-for-children-and-adolescents>
- WHO. (2021e). *Media Statement: Knowing the risks for COVID-19*. <https://www.who.int/indonesia/news/detail/08-03-2020-knowing-the-risk-for-covid-19>
- WHO. (2021f). *Safety Of COVID-19 Vaccines*. World Health Organization. <https://www.who.int/news-room/feature-stories/detail/safety-of-covid-19-vaccines>
- WHO. (2021g). *The Janssen Ad26.COV2.S COVID-19 vaccine: What you need to know*. <https://www.who.int/news-room/feature-stories/detail/the-j-j-covid-19-vaccine-what-you-need-to-know>
- WHO. (2021h). *The Oxford/AstraZeneca COVID-19 vaccine: what you need to know*. <https://www.who.int/news-room/feature-stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know>
- WHO. (2021i). *The Pfizer BioNTech (BNT162b2) COVID-19 vaccine: What you need to know*. <https://www.who.int/news-room/feature-stories/detail/who-can-take-the-pfizer-biontech-covid-19--vaccine>
- WHO. (2021j). *The Sinopharm COVID-19 vaccine: What you need to know*. <https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know>
- WHO. (2021k). *The Sinovac-CoronaVac COVID-19 vaccine: What you need to know*. <https://www.who.int/news-room/feature-stories/detail/the-sinovac-covid-19-vaccine-what-you-need-to-know>
- WHO. (2021l). *WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations*. <https://www.who.int/news/item/01-06-2021-who-validates-sinovac-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations>
- WHO. (2022). *Statement on the tenth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic*. World Health Organization. [https://www.who.int/news/item/19-01-2022-statement-on-the-tenth-meeting-of-the-international-health-regulations-\(2005\)-emergency-committee-regarding-the-coronavirus-disease-\(covid-19\)-pandemic](https://www.who.int/news/item/19-01-2022-statement-on-the-tenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic)
- Wibawa, T. (2021). *COVID-19 vaccine research and development: ethical issues*. *Tropical Medicine and International Health*, 26(1), 14–19. <https://doi.org/10.1111/tmi.13503>
- Yesudhas, D., Srivastava, A., & Gromiha, M. M. (2021). *COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics*. *Infection*, 49(2), 199–213. <https://doi.org/10.1007/s15010-020-01516-2>

Yuliana, A., Ruswanto, M.S., Apt, F.G. and Farm, M., 2021. Covid-19: Pandemi yang Menyerang Bumi Kami. Jakad Media Publishing.

Zhao, H., Li, Y., & Wang, Z. (2021). *Adverse event of Sinovac Coronavirus vaccine: Deafness. Vaccine, 40(3), 521–523.*
<https://doi.org/10.1016/j.vaccine.2021.11.091>